You are here

Structural & Congenital Heart Disease

 

Next-day discharge after minimalist transcatheter aortic valve replacement (TAVR) was safe for patients who didn’t experience perioperative complications and was linked to better one-year outcomes versus patients discharged later, according to a single-center study published in JACC: Cardiovascular Interventions.

The American Heart Association (AHA) and American College of Cardiology (ACC) rolled out new guidelines for managing valvular heart disease (VHD) in 2017, marking the second overhaul of VHD recommendations in three years—a move attributable to “extensive new data” that have shaped the way clinicians treat valve disease.

A larger valve option and more appropriate valve sizing using preprocedural imaging may eliminate the previously reported survival disparity between men and women undergoing transcatheter aortic valve replacement (TAVR), a new study in JACC: Cardiovascular Interventions suggests.

Procedures to replace or repair patients’ tricuspid valves (TVs) remain rare but have increased in recent years, according to a study in the Journal of the American College of Cardiology. But despite this increased volume, in-hospital mortality has remained steady at 8.8 percent.

The Centera transcatheter heart valve (THV) shows promise in addressing the “Achilles’ heel” of transcatheter aortic valve replacement (TAVR), according to Luis Nombela-Franco, MD, PhD, who wrote an editorial about the device’s pivotal study published in the Journal of the American College of Cardiology.

 

Recent Headlines

Artificial sweeteners linked to heart disease, other conditions

A new study by researchers in Canada has found an association between artificial sweeteners and an increased risk for heart disease and other conditions related to it.

Scientists develop silicone heart using 3D printing

Scientists at ETH Zurich in Switzerland have managed to create a silicone heart that works and pumps blood like a biological human heart. The only problem is that it doesn’t have the stamina of a real one.

Scottish study strengthens link between high BMI, cardiometabolic disease risk

New research published this week adds to existing evidence that there’s an association between high body mass index (BMI) and an increased risk of cardiometabolic diseases like hypertension, coronary heart disease and type 2 diabetes.

Time of year, day of week could influence incidence of MI

New research suggests that certain times of year or days of the week could have an effect on the incidence of myocardial infarction (MI).

FDA, health orgs encourage better ways to test heart drugs in children

In a new health policy statement, the U.S. Food and Drug Administration (FDA) and other major health organizations have called for improvements in the way medications are developed and tested in children with heart disease.

Making the Call for Closure: Heart–Brain Teams Strive to Improve Patient Selection for PFO Closure

Did the patent foramen ovale (PFO) cause the patient’s stroke? This, experts say, is the key question when deciding whether to recommend PFO closure. Heart–brain teams can help with the answer.   

A Practical Guide to Palliative Care for Heart Failure Patients

With a few practical steps, cardiology practices can meet the palliative care needs of heart failure patients.     

Healing hearts, one molecule at a time

We cut a finger and the skin heals. But what if hearts could heal too? Researchers recently found a molecule in newborns that might help, some day. The team at the Weizmann Institute of Science have identified a molecule found in newborns that appears to control the renewal process, assisting regeneration in damaged hearts.

Scientists ID cell that can regenerate heart tissue after MI

Researchers at the Weizmann Institute of Science in Israel have uncovered a molecule found in newborns that aids in regenerating damaged hearts—and are now testing ways that the molecule could treat heart attack victims.

Amgen seeks market approval for Repatha in U.S., Europe

Thousand Oaks, California-based Amgen has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration (FDA) and a variation of one in Europe seeking approval for Repatha, a PCSK9 inhibitor.

Pages